Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease

Diane E Milenic*, Kwamena E Baidoo, Young-Seung Kim, and Martin W Brechbiel

Radioimmune & Inorganic Chemistry Section; Radiation Oncology Branch; Center for Cancer Research; National Cancer Institute; National Institutes of Health; Bethesda MD USA

Although the epidermal growth factor receptor (EGFR), also known as HER1, has been studied for over a decade, it continues to be a molecule of great interest and focus of investigators for development of targeted therapies. The marketed monoclonal antibody cetuximab binds to HER1, and thus might serve as the basis for creation of imaging or therapies that target this receptor. The potential of cetuximab as a vehicle for the delivery of α-particle radiation was investigated in an intraperitoneal tumor mouse model. The effective working dose of 10 μCi of ^{212}Pb-cetuximab was determined from a dose (10–50 μCi) escalation study. Toxicity, as indicated by the lack of animal weight loss, was not evident at the 10 μCi dose of ^{212}Pb-cetuximab. A subsequent study demonstrated ^{212}Pb-cetuximab had a therapeutic efficacy similar to that of ^{212}Pb-trastuzumab (p = 0.588). Gemcitabine given 24 h prior to ^{212}Pb-cetuximab increased the median survival from 174 d to 283 d, but carboplatin suppressed the effectiveness of ^{212}Pb-cetuximab. Notably, concurrent treatment of tumor-bearing mice with ^{212}Pb-labeled cetuximab and trastuzumab provided therapeutic benefit that was greater than either antibody alone. In conclusion, cetuximab proved to be an effective vehicle for targeting HER1-expressing tumors with α-radiation for the treatment of disseminated intraperitoneal disease. These studies provide further evidence that the multimodality therapy regimens may have greater efficacy and benefit in the treatment of cancer patients.

Introduction

To date, studies from this laboratory have focused on targeting human epidermal growth factor receptor 2 (HER2)-expressing tumors with ^{212}Pb and ^{213}Bi using trastuzumab as the delivery vehicle. Targeting HER2 with α-particle radiation has proven successful in treating disseminated peritoneal disease. Trastuzumab labeled with either ^{213}Bi or ^{212}Pb extended the median survival of mice bearing intraperitoneal (i.p.) tumors by 3- to 4-fold.[1,2] This therapeutic benefit can be potentiated by incorporating chemotherapeutics such as gemcitabine, paclitaxel or carboplatin into the treatment regimen.[3-5]

^{213}Bismuth, a decay product of ^{225}Ac, has a $T_{1/2}$ of 45.7 min whereas ^{212}Pb is a 10.6 h half-life β$^{−}$-emitter that decays to ^{212}Bi, an α-emitter with a $T_{1/2}$ of 60.6 min. The strategy of exploiting ^{212}Pb as an in vivo generator of ^{212}Bi, overcomes the disadvantages of a shorter half-life radionuclide. In fact, a ^{212}Pb-labeled monoclonal antibody (mAb) can deliver >10 times the dose of a mAb labeled with a bismuth radioisotope. Most of the dose delivered to the cell comes from the α-decays of the ^{212}Pb daughters, ^{212}Bi and ^{212}Po.[6] When ^{212}Pb decays, up to 36% of the ^{212}Bi could be lost from the chelate as a result of recoil. Loss of the ^{212}Bi appears not to be particularly problematic if the radioimmunoconjugate is injected intraperitoneally.[7]

The success of the investigations with ^{212}Pb has led to their translation into a clinical study at the University of Alabama. Initiated in July 2011, this study (NCT01384253) is assessing the safety of ^{22}Pb-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoyl methyl)-cyclododecane–trastuzumab (^{22}Pb-TCMC-trastuzumab) radioimmunotherapy (RIT) administered by i.p. injection. Patients under recruitment are those with HER2-positive peritoneal neoplasms of ovarian, pancreatic and gastric origin. At this juncture, no adverse reactions or toxicities have been reported for patients receiving ^{212}Pb-trastuzumab.[8] This clinical study has now been extended to a second site at the University of California at San Diego.

More recent studies within the laboratory have focused on elucidating the mechanism(s) by which the α-targeted therapy

*Correspondence to: Diane E Milenic; Email: milenicd@mail.nih.gov

invokes effective tumor cell death. Targeting LS-174T tumors with [212]Pb-trastuzumab increases DNA double-stranded breaks, impairs DNA damage repair, persistent G2/M arrest and chromatin remodeling.[9,10]

HER2 is expressed by an array of epithelial cancers such as pancreas (35–45%), breast (25–30%), ovarian (25–100%) and colorectal (up to 90%).[11–14] Conversely, one might also state that HER2, for example, is not well expressed in 55–65% of pancreatic cancers, and therefore identification of additional molecular targets is warranted to expand the repertoire of α-targeted RIT. The epidermal growth factor receptor (EGFR; HER1) is one such possibility. HER1 is over-expressed in pancreatic, head and neck, breast, renal, colorectal, prostate, ovarian, bladder and breast cancer. This target is also overexpressed in malignancies such as glioma and mesothelioma.[15–17]

First approved in 2004, cetuximab is indicated for the treatment of patients with HER1-positive metastatic colorectal cancer, either in combination with irinotecan, or without, dependent on the patient's tolerance. Cetuximab therapy has been found to reduce tumor burden and delay tumor growth in some patients, but does not necessarily extend patients' lives.[18–20] The advantage of RIT is that its effectiveness is not dependent on the pharmacological effect of the targeting vector's biological interaction with its target, i.e., cetuximab's interaction with HER1. Furthermore, RIT does not require high expression of the target molecule. Nevertheless, cetuximab has potential as a radiotherapeutic agent. Several imaging investigations have explored the practicality of using cetuximab for monitoring disease, assaying EGFR expression, determining patient selection as well as for performing dosimetric calculations for RIT.[21-26] The possibility that cetuximab might be appropriate for RIT applications was demonstrated in a set of studies published by this laboratory.[23] Tumor targeting of ^{111}In-cetuximab was validated in 5 tumor models by direct quantitation of tumor tissue and with γ-scintigraphy. The usefulness of cetuximab was also confirmed in a study in which cetuximab labeled with [86]Y was studied for positron-emission tomography (PET) imaging.[24,25]

The studies described herein are both exploratory and confirmatory to the above hypothesis, evaluating the potential of cetuximab for α-targeted therapy of disseminated intraperitoneal disease. Consistent with previous studies from this laboratory, this investigation also includes studies combining chemotherapeutics (gemcitabine and carboplatin) with RIT to assess potential therapeutic efficacy enhancement of HER1 targeting α-emitting high-LET [212]Pb-labeled cetuximab. The ultimate goal is to establish a multimodality regimen, using multiple targeting vehicles, for the management of cancer patients with disseminated intraperitoneal disease.

Results

In vitro analysis of cetuximab-TCMC and [212]Pb-cetuximab

Conjugations of cetuximab with TCMC proved routine. When performed at a 10:1 molar ratio of TCMC:cetuximab, a final chelate-to-cetuximab ratio of 4.2 ± 2.1 was obtained. The

Figure 1. Evaluation of cetuximab-TCMC immunoreactivity. The imunoreactivity of cetuximab-TCMC (○) was evaluated in a competition radioimmunoassay using purified human EGFR. The immunoconjugate was compared to unmodified cetuximab (●). HuM195 (----), a mAb that recognizes CD-33, was used as a negative control.

immunoreactivity of the cetuximab-TCMC conjugate was maintained compared to unmodified cetuximab in a competition radioimmunoassay (**Fig. 1**). Radiolabeling the TCMC-cetuximab conjugate was likewise consistent with results that are obtained with trastuzumab. The cetuximab labeling was efficient (65%), achieving an average specific activity of 4 mCi/mg. The immunoreactivity of the [212]Pb-cetuximab was evaluated in a radioimmunoassay using purified recombinant human EGFR. After a 4 h incubation at 37°C, the percent bound of [212]Pb-cetuximab was 78%. Addition of unlabeled cetuximab to one set of wells reduced the amount bound to 0.9%, thus demonstrating retention of specificity by the [212]Pb-cetuximab.

Validation of tumor targeting of radiolabeled cetuximab in an i.p. tumor xenograft model

Previous publications from this laboratory demonstrated the feasibility of targeting HER1 with radiolabeled cetuximab (^{111}In or [86]Y) for the management of a range of cancers, included ovarian, colon, prostate, pancreatic and mesothelioma.[23–25] These studies were performed with mice bearing subcutaneous (s.c.) tumor xenografts and the radiolabeled cetuximab given by an intravenous (i.v.) route. The first step in the current series of studies, therefore, was to appraise the targeting qualities of cetuximab in the i.p. model to determine if further pursuit of this mAb for targeted α-radiation therapy of disseminated peritoneal disease was valid.

Athymic mice with i.p. LS-174T xenografts (n = 5) were injected (i.p.) with ^{111}In-cetuximab to establish and define tumor targeting as well as normal organ distribution of the radioimmunoconjugate. Detailed in **Fig. 2A**, the ^{111}In-CHX-A"-cetuximab demonstrates excellent targeting of the i.p. tumors with a tumor

percent injected dose per gram (%ID/g) of 51.8 ± 26.4 at 24 hr. The tumor%ID/g then decreases through the 1 week study period to 37.8 ± 20.5, 34.8 ± 31.8, 21.1 ± 2.2 and 8.3 ± 3.2 at 48, 72, 144 and 168 h, respectively. This decrease in the tumor%ID/g reflects the aggressive nature of the rapidly growing LS-174T tumor. At 24 h, the average weight of the tumor tissue harvested from the mice was 147 ± 102 mg. By the end of the study, at 168 h, the average amount of tumor collected was 1,362 ± 802 mg. When the amount of radioactivity in the tumor is calculated and plotted (**Fig. 2B**), the cpm (decay corrected) was found to be relatively constant through the study, demonstrating a decreasing trend that is not as dramatic as that perceived in the %ID/g vs. time plot.

Of the normal organs, the highest %ID/g was observed in the liver (26.8 ± 3.4) and the spleen (24.5 ± 6.2) at 24 h; both decreased by 168 h (4.0 ± 1.1 and 5.8 ± 2.2, respectively). The high %ID/g of these normal organs at 24 h and subsequent

decrease corresponds with the trend observed in the blood. The blood presented with the next highest %ID/g at 24 h with a value of 23.1 ± 7.86 and ended with %ID/g of 0.5 ± 0.22 at 168 h.

Determination of effective therapeutic dose of ^{212}Pb-cetuximab

Having validated i.p. injected cetuximab as a vehicle for targeting i.p. tumor xenografts, a therapy study was then designed and performed to establish an effective therapeutic dose. When combining cetuximab RIT with chemotherapeutics, the lower range of the maximum effective therapeutic dose is desired to avoid obscuring any potentiation of therapy.

Athymic mice bearing a 3 d i.p. tumor (LS-174T) burden were injected i.p. with increasing doses (10–40 μCi) of ^{212}Pb-cetuximab. As illustrated in **Figure 3**, therapeutic efficacy was observed at all doses. A median survival (MS) of >294, 148, 235 and 223 d was achieved with 10, 20, 30 and 40 μCi of ^{212}Pb-cetuximab, respectively (p = < 0.001). A MS, in fact, could not be determined for the 10 μCi treatment group. At 294 d, when the experiment was terminated, 6 of 10 mice were still alive. Compared to the set of mice that were not treated (28 d MS), this represents a therapeutic index (treatment MS divided by the untreated MS) of >10.5, 5.3, 8.4 and 8.0 for the mice treated with 10, 20, 30 and 40 μCi of ^{212}Pb-cetuximab, respectively. In contrast, the mice treated with 20 and 40 μCi of ^{212}Pb-HuIgG, experienced a MS of 33 and 50 d, corresponding to only 1.2 (p = 0.936) and 1.8-fold (p = 0.796) greater than that of the untreated group. There was a significant difference between the groups that received 20 μCi (p = 0.004) or 40 uCi (p = 0.022) of ^{212}Pb-labeled cetuximab and HuIgG.


Figure 2. Tumor and normal tissue distribution of ^{111}In-cetuximab. (**A**) Athymic mice bearing 5 d LS-174T i.p. tumor xenografts were injected i.p. with ^{111}In-cetuximab (∼7.5 μCi). The mice (n = 5) were euthanized at 24 (▦), 48 (◨), 72 (◩), 144 (⊠) and 168 h (■) after the injection. The tumor and tissues were harvested, wet-weighed and the radioactivity measured in a γ-counter. The%ID/g and standard deviation were calculated. (**B**) The average cpm of the tumor and tissues was also calculated as well as the standard deviation.

Figure 3. Effect of increasing doses of ^{212}Pb-cetuximab. Kaplan-Meier survival curves of mice (n = 10) bearing i.p. LS-174T tumor xenografts and treated with increasing doses of i.p. injected ^{212}Pb-cetuximab (10, 20, 30 and 40 μCi) or the control antibody, ^{212}Pb-HuIgG (20 and 40 μCi) and compared to a group of mice that were not treated.

Table 1. Effect of increasing doses [212]Pb-cetuximab i.p. therapy on the weights of athymic mice bearing LS-174T i.p. tumor xenografts

RIT	Dose	0	9	16	21	24	28
				Days			
None		25.2 ± 1.8	26.5 ± 2.5	26.0 ± 3.6	25.9 ± 3.1	25.4 ± 4.5	24.9 ± 4.8
Cetuximab	10 μCi	25.3 ± 0.8	25.6 ± 1.4	25.5 ± 1.8	25.7 ± 1.4	25.6 ± 1.5	26.0 ± 1.3
	20 μCi	25.6 ± 2.0	24.9 ± 3.2	26.1 ± 2.9	25.8 ± 2.4	25.7 ± 2.2	26.5 ± 2.1
	30 μCi	25.0 ± 1.4	22.8 ± 1.7	25.2 ± 1.9	24.6 ± 1.8	24.7 ± 1.9	24.7 ± 1.8
	40 μCi	25.3 ± 1.3	23.7 ± 1.4	24.5 ± 1.3	24.6 ± 1.3	25.5 ± 1.3	25.5 ± 1.4
HuIgG	20 μCi	25.6 ± 1.4	23.2 ± 2.2	23.9 ± 2.3	23.4 ± 2.4	23.3 ± 2.3	24.3 ± 2.0
	40 μCi	26.4 ± 1.3	22.8 ± 1.4	23.5 ± 1.8	23.4 ± 1.4	23.4 ± 1.6	23.5 ± 1.8

Animal weights were monitored as an indicator of toxicity following treatment with escalating doses of [212]Pb-cetuximab. Additional groups included untreated and 2 doses (20 and 40 μCi) of [212]Pb-HuIgG.

Examination of (**Table 1**) the animals' weights, used as an indicator of toxicity, showed that, among the groups injected with [212]Pb-cetuximab, the 30 μCi and 40 μCi groups lost 8.8% and 9.1% of their body weight, respectively, 9 d after treatment. However, after 4 weeks, the mice appear to have recovered because they attained the body weight recorded at the beginning of the therapy study. The 20 μCi group experienced a modest weight loss of 2.8% after 9 d and the group treated with 10 μCi of [212]Pb-cetuximab showed no weight loss. There was no statistical difference between the weights of the untreated group and the groups receiving either 10 μCi ($p = 0.4656$) or 20 μCi ($p = 0.1008$) of [212]Pb-cetuximab. In contrast, the weight loss was more dramatic in the mice receiving the [212]Pb-HuIgG; at 11 d there was a weight loss of 24% for the 20 μCi dose ($p = 0.0060$) and 36% for the 40 μCi ($p = 0.0029$). This latter group of mice did not regain weight. Simply based on the superior therapeutic index along with the lack of "toxicity," 10 μCi was chosen as the effective therapeutic dose for subsequent studies with [212]Pb-cetuximab, thereby also making a direct comparison with [212]Pb-trastuzumab possible.

Confirmation of [212]Pb-cetuximab dose for subsequent RIT studies

An experiment to validate the dose of [212]Pb-cetuximab was then performed. In the same study, the therapeutic efficacy of targeting HER1 with [212]Pb-cetuximab was compared to that of targeting HER2 with [212]Pb-trastuzumab. Cohorts of 10 mice each, bearing i.p. LS-174T tumor xenografts, were treated with 10 μCi of [212]Pb-labeled cetuximab, trastuzumab or the non-specific polyclonal [212]Pb-HuIgG. While, [212]Pb-cetuximab was effective with a MS of 84 d and a therapeutic index of 4.2 (**Fig. 4**), greater therapeutic efficacy was observed with [212]Pb-trastuzumab with a MS of 113 d and a therapeutic index of 5.7. The differences in survival of the two groups, however, were not significant ($p = 0.588$). As is usually observed, the [212]Pb-HuIgG also provided some therapy with a MS of 34 d. All groups are compared to the untreated group of mice with a MS of 20 d. To determine whether or not unlabeled cetuximab alone had any therapeutic effect on the LS-174T tumor xenografts, one set of mice (n = 10) was treated with 2 mg of cetuximab. With a MS of 13 d, cetuximab alone at this protein dose and scheduling does not appear to have any therapeutic effect on the LS-174T tumor xenografts. Consistent with the previous experiment, no weight loss was observed in the tumor-bearing mice treated with 10 μCi of [212]Pb-cetuximab. There was also no weight loss in the groups that were injected with [212]Pb-trastuzumab, HuIgG or the unlabeled cetuximab (data not presented).

Figure 4. Validation of the effective working dose of [212]Pb-cetuximab therapy. Kaplan-Meier survival curves of mice (n = 10) bearing i.p. LS-174T tumor xenografts were injected i.p. with 10 μCi [212]Pb-labeled cetuximab and compared to [212]Pb-trastuzumab. Additional groups of mice included untreated and [212]Pb-HuIgG. Another group of mice received a single dose of unlabeled cetuximab (2 mg).

Table 2. Median survival (days) of athymic mice bearing i.p. LS-174T xenografts following i.p. administration of [212]Pb-cetuximab and chemotherapeutics

Chemotherapeutic	None	Cetuximab	HuIgG
		Radioimmunotherapy	
None	24	174 (7.3)	24 (1.0)
Gemcitabine	24 (1.0)[a]	283 (11.8)	49 (2.0)
Carboplatin	31 (1.3)	80 (3.3)	43 (1.8)

[a]The values in parentheses are the therapeutic indices (median survival of the treatment group divided by the median survival of untreated group). The gemcitabine and carboplatin were injected 24 h prior to [212]Pb-RIT administration.

Table 3. Effect of chemotherapeutics in combination with ^{212}Pb-radioimmunotherapy on the weights of athymic mice bearing LS-174T i.p. tumor xenografts

		Days Post Radioimmunotherapy							
RIT	Chemotherapy	−1	7	11	14	18	21	25	28
None	None	24.2 ± 1.9a	24.3 ± 1.9	24.1 ± 2.6	23.6 ± 2.2	23.8 ± 2.5	26.0 ± 2.1	25.3 ± 1.6	25.2 ± 1.1
Cetuximab	None	25.5 ± 1.6	23.1 ± 2.6	24.2 ± 2.8	24.3 ± 2.5	24.6 ± 3.2	25.7 ± 2.9	25.3 ± 3.0	25.6 ± 3.0
HuIgG	None	25.1 ± 1.8	23.3 ± 2.7	24.4 ± 2.7	24.9 ± 2.5	25.1 ± 2.8	25.8 ± 2.4	25.2 ± 2.3	26.2 ± 2.3
None	GEM	23.5 ± 1.4	23.3 ± 2.1	23.7 ± 2.3	23.8 ± 2.4	23.7 ± 1.6	25.4 ± 1.2	24.6 ± 1.6	24.8 ± 2.1
Cetuximab	GEM	25.1 ± 1.9	22.2 ± 1.9	24.1 ± 2.6	24.8 ± 2.6	25.2 ± 2.9	26.7 ± 2.5	26.5 ± 2.6	25.5 ± 2.2
HuIgG	GEM	25.6 ± 2.1	23.6 ± 3.0	24.1 ± 3.5	26.0 ± 2.6	25.9 ± 3.2	25.9 ± 2.6	26.3 ± 1.8	26.9 ± 1.9
None	Carboplatin	24.8 ± 1.9	24.9 ± 2.6	25.6 ± 2.4	25.1 ± 2.5	24.8 ± 2.5	27.3 ± 2.1	26.8 ± 1.9	25.7 ± 0.4
Cetuximab	Carboplatin	24.6 ± 3.0	21.5 ± 3.0	22.7 ± 2.8	25.5 ± 3.1	25.0 ± 4.1	25.6 ± 3.9	26.2 ± 3.0	26.2 ± 3.9
HuIgG	Carboplatin	25.6 ± 1.5	24.4 ± 2.4	24.7 ± 3.0	25.6 ± 2.8	24.9 ± 3.0	26.7 ± 1.8	26.3 ± 1.5	26.6 ± 1.5

aAthymic mice bearing i.p. LS-174T tumor xenografts were administered an i.p. injection of gemcitabine or carboplatin and ^{212}Pb-labeled cetuximab or HuIgG. The values presented are the average weight (g) of mice along with the standard deviation.

Combination of chemotherapeutics with ^{212}Pb-cetuximab therapy

The next round of studies focused on the potentiation of HER1-targeted RIT by chemotherapeutics. Previous studies from this laboratory combining gemcitabine (GEM), paclitaxel or carboplatin with ^{213}Bi- or ^{212}Pb-labeled trastuzumab have demonstrated augmentation of RIT efficacy. The pretreatment of mice bearing i.p. tumor (LS-174T) xenografts (**Table 2**), 24 h prior to injection of ^{212}Pb-cetuximab (10 μCi), with 1 mg of GEM improved the median survival (283 d) by 109 d compared to mice that received ^{212}Pb-cetuximab only (MS of 174 d). This increase in MS translates to a therapeutic index of 11.8, but it was not significant when compared to the group treated with ^{212}Pb-cetuximab alone (p = 0.724). Consistent with previous reports from this laboratory, the GEM pretreatment also resulted in an increase in the therapeutic efficacy of the ^{212}Pb-HuIgG group. In this instance, the MS was 49 d, a 2-fold increase in survival compared to the mice treated with only the ^{212}Pb-HuIgG.

Each of the treatment groups experienced weight loss 1 week after RIT administration (**Table 3**). The greatest weight loss (2.9 g) was observed in the group that received the combination of GEM and ^{212}Pb-cetuximab; this weight loss was statistically significant compared to the control group (p = 0.0058). The next greatest weight loss was observed in the group of mice treated with GEM alone (2.4 g; p = 0.341). Recovery from the weight, in all treatment groups, was evident 11–14 d post-RIT. Complete recovery from the weight loss occurred 25–28 d post RIT.

The combination of carboplatin with ^{212}Pb-cetuximab proved less successful. Following the same i.p. administration schedule as was determined with ^{212}Pb-trastuzumab, carboplatin (1.25 mg) was injected concurrently with the ^{212}Pb-RIT (**Table 2**).[3] Carboplatin alone resulted in a modest therapeutic effect on the LS-174T i.p. tumor xenografts with a MS of 31 d and a therapeutic index of 1.3. When combined with ^{212}Pb-cetuximab, a MS of 80 d with a therapeutic index of 3.3 was realized. The carboplatin combined with ^{212}Pb-HuIgG also provided some therapeutic benefit with a MS of 43 d, but this result does not compare well to the MS of 174 d in the group of tumor-bearing mice that received just the ^{212}Pb-cetuximab.

Again, weight loss, which ranged from 1.3 to 3.2 g, occurred by 7 d post-RIT in each of the treatment groups, with the exception of the group treated with only carboplatin (**Table 3**). The greatest loss was observed in the mice treated with the carboplatin and ^{212}Pb-cetuximab (p = 0.034). Recovery from the weight loss was detected as early as 11 d, and was evident in all of the affected groups by 21 d.

## Targeting of multiple antigens to augment efficacy of ^{212}Pb RIT

The targeting of multiple distinct molecules in tumors is another strategy being pursued by investigators in the field of RIT.[27-31] A pilot study was conducted to explore the potential of dual targeting of HER2 and HER1 with ^{212}Pb-labeled mAbs as a natural extension of the studies described herein.

Tumor-bearing mice treated with 10 μCi of ^{212}Pb-labeled cetuximab or trastuzumab experienced a MS of 147 and 182 d, respectively, an improvement in survival of 7.4- and 9.1-fold compared to the untreated group (**Fig. 5**, **Table 4**). When tumor-bearing mice were treated with a formulation of 5 μCi ^{212}Pb-cetuximab and 5 μCi ^{212}Pb-trastuzumab, the MS was 219 d, which translates into a therapeutic index of 11. Some therapeutic benefit was derived from the combination of ^{212}Pb-labeled cetuximab/HuIgG (MS = 63 d) and trastuzumab/HuIgG (MS = 71 d).

The greatest weight loss was observed in the groups that received ^{212}Pb-cetuximab/^{212}Pb-HuIgG (8.2% loss) and ^{212}Pb-trastuzumb/^{212}Pb-HuIgG (6.8% loss). The mice receiving the combination of ^{212}Pb-cetuximab and ^{212}Pb-trastuzumab maintained their weight following the treatmen*t* (**Table 5**).

Discussion

The ultimate objective of studies within this laboratory is to develop a multi-modality treatment regimen for cancer patients with residual tumor tissue following surgical debulking/resection, micrometastic tumor or disseminated peritoneal disease. Having established that α-particle radiation has great potential in the

Figure 5. Targeting of multiple antigens to augment efficacy of [212]Pb RIT. Kaplan-Meier survival curves of mice (n = 10) bearing i.p. LS-174T tumor xenografts were co-injected i.p. with 5 µCi each of [212]Pb-cetuximab and [212]Pb-trastuzumab. These were compared to groups injected with the combination of [212]Pb-cetuximab / [212]Pb-HuIgG and [212]Pb-trastuzumab / [212]Pb-HuIgG. Additional groups of mice included untreated, [212]Pb-cetuximab, [212]Pb-trastuzumab and [212]Pb-HuIgG. A total of 10 µCi [212]Pb was administered to each mouse.

Table 4. Median survival (days) of athymic mice bearing i.p. LS-174T xenografts following dual administration (i.p.) of [212]Pb-labeled cetuximab and trastuzumab targeting HER1 and HER2

Vehicle	Target	Median Survival	Therapeutic Index
None	None	20	1.0
Cetuximab	HER1	147	7.4
Trastuzumab	HER2	182	9.1
HuIgG	None	29	1.5
Cetuximab/Trastuzumab	HER1/HER2	219	11.0
Cetuximab/HuIgG	HER1/None	63	3.2
Trastuzumab/HuIgG	HER2/None	71	3.6

The therapeutic indices are the median survival of the treatment group divided by the median survival of untreated group.

treatment of cancers such as pancreatic, ovarian and others that can present as disseminated intraperitoneal disease, using [213]Bi- and [212]Pb-labeled trastuzumab to target HER2, subsequent studies have concentrated on exploring the potential of integration of chemotherapeutics (gemcitabine, paclitaxel and carboplatin) to enhance the efficacy of α-RIT. Adding cetuximab, which targets HER1, would provide another possibility or combination for the treatment and management of cancer patients.

The epidermal growth factor receptor, EGFR/HER1, continues to be a molecule of great interest and focus of investigators for the development of targeted therapies. Primarily, the strategy has been to inhibit or block the activation of tyrosine kinase

(TK) by using small molecule inhibitors or large molecules such as mAbs. The former exert their effect intracellularly, preventing TK phosphorylation, while the latter interact with the extracellular domains of the receptor, blocking ligand binding. When combined with other chemotherapeutics or radiation, EGFR inhibitors have been shown to potentiate therapeutic efficacy. Two HER1-binding mAbs, cetuximab (Erbitux®) and panitumumab (Vectibix®), have been approved by the US Food and Drug Administration. Both mAbs have demonstrated sensitization of tumor cells to chemotherapy and radiation in pre-clinical and clinical studies.[32–34]

Studies from this laboratory and others have reported on the potential of HER1 as a target for molecular imaging and for targeted radiation therapy.[21-24,26,35-38] Cetuximab has been the focus of several imaging studies with the objective of assessing the value of this mAb for disease monitoring, HER1 expression and distribution, patient selection and for performing dosimetric calculations.[23-26] The preclinical studies from this laboratory demonstrated excellent targeting of s.c. tumor by ^{111}In-cetuximab given intravenously.[23] Targeting was obtained in 5 tumor models (2 colorectal, 1 prostate, 1 pancreatic and 1 ovarian), determined by direct quantitation of tissues and by planar γ-scintigraphy.[23] Meanwhile, minimal normal tissue uptake was also observed in these models, as well as in a melanoma tumor model (A375) in which tumor uptake of the radioimmunoconjugate was also minimal. The studies were extended to evaluating cetuximab for positron-emissions tomography (PET) imaging. PET imaging was

Table 5. Effect of dual targeting using dual targeted [212]Pb-radioimmunotherapy on the weights of athymic mice bearing LS-174T i.p. tumor xenografts

RIT	Days Post Radioimmunotherapy								
	−4	5	9	12	16	19	23	25	30
Untreated	27.2 ± 1.2	27.6 ± 1.1	27.6 ± 1.3	27.0 ± 1.3	26.9 ± 0.9	28.0 ± 2.0	26.8 ± 2.3	27.8	28.3
Cetuximab	26.6 ± 1.1	26.6 ± 1.7	27.2 ± 1.6	27.3 ± 2.0	27.8 ± 2.2	27.8 ± 2.7	27.9 ± 2.5	28.2 ± 2.9	28.1 ± 2.7
Trastuzumab	24.6 ± 2.0	23.8 ± 2.3	25.5 ± 2.4	25.1 ± 2.6	26.2 ± 2.6	26.2 ± 2.9	25.6 ± 2.4	25.9 ± 2.3	26.0 ± 2.3
HuIgG	25.4 ± 0.8	24.5 ± 2.4	25.5 ± 3.4	24.7 ± 1.4	26.3 ± 2.8	27.1 ± 2.1	26.6 ± 1.8	26.9 ± 2.4	27.6 ± 1.7
Cetuximab/Trastuzumab	25.6 ± 1.1	26.0 ± 1.7	27.1 ± 1.5	27.0 ± 1.8	27.2 ± 2.8	27.6 ± 1.4	27.4 ± 1.5	27.6 ± 1.5	28.0 ± 1.3
Cetuximab/HuIgG	25.6 ± 2.1	23.5 ± 2.2	24.7 ± 1.6	24.6 ± 1.7	25.4 ± 1.9	25.6 ± 2.2	25.5 ± 1.7	25.6 ± 1.9	26.1 ± 1.6
Trastuzumab/HuIgG	26.4 ± 1.7	24.6 ± 2.2	25.7 ± 2.4	25.9 ± 2.7	26.8 ± 2.7	27.0 ± 2.7	27.0 ± 2.4	26.6 ± 2.5	26.9 ± 2.7

Athymic mice bearing i.p. LS-174T tumor xenografts were injected with [212]Pb-labeled cetuximab, trastuzumab, HuIgG or combinations as indicated. The values presented are the average weight (g) of mice along with the standard deviation.

performed with the models mentioned above using cetuximab radiolabeled with [86]Y using the 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A"-DTPA) chelate along with 3 additional models for mesothelioma.[24,25] The results from all of these studies suggest that cetuximab not only has potential as a diagnostic agent, but also for RIT applications.

This hypothesis is corroborated by the available literature. Imaging has been demonstrated using either [64]Cu- or [89]Zr-cetuximab, while therapy has been conducted with [90]Y- or ^{177}Lu-cetuximab.[21,22,26,37] Unfortunately, close inspection of these reports reveals a range of problems with study design. In the case of ^{64}Cu, the chelate/Cu complex was not stable and ^{64}Cu was steadily released from the radioimmunoconjugate to be sequestered in normal tissue. The use of [89]Zr for PET imaging currently presents with the same problem.[39,40] Cetuximab radiolabeled with ^{177}Lu appears promising. The treatment of mice bearing s.c. head and neck tumor xenografts with a single dose of ^{177}Lu-cetuximab resulted in a ∼3 week delay of tumor growth.[21] In this instance however, a negative ^{177}Lu-labeled control was not included in the study to account for the effect of non-specific radiation. At this juncture, to the best knowledge of the authors, this study represents the first report in which cetuximab is used to target HER1-expressing tumors with α-particle radiation.

Although studies from this laboratory had shown tumor targeting of ^{111}In-cetuximab in a s.c. model, it was deemed necessary to establish that i.p. administration of ^{111}In-cetuximab would be just as effective. Indeed, the locoregional delivery of the radioimmunoconjugate proved as successful, attaining a tumor-%ID/g at 24 h that was comparable to that published for a s.c. tumor xenograft at 72 h.[23] With this encouraging result, radioimmunotherapy studies were conducted.

As mentioned, the conjugation of cetuximab with the TCMC chelate and subsequent labeling with [212]Pb was routine and were well tolerated by the mAb. The chelate:mAb ratio were consistent with prior results obtained with the conjugation of trastuzumab with the TCMC ligand. Mice tolerated the 10 or 20 μCi of [212]Pb-cetuximab with minimal indications of toxicity. Anticipating that [212]Pb-cetuximab would be assessed in combination with chemotherapeutic agents, the 10 μCi dose was selected as the effective "working" dose. As stated earlier, the lower range of the maximum effective therapeutic dose is desired to avoid obscuring any potentiation of therapy by the chemotherapeutic. A direct comparison of [212]Pb-cetuximab with [212]Pb-trastuzumab established [212]Pb-cetuximab as a viable radioimmunotherapeutic agent. Differences in the therapeutic efficacy of the 2 radioimmunoconjugates were not significant.

Pre-treatment of tumor-bearing mice with gemcitabine prior to [212]Pb-cetuximab augmented the therapeutic efficacy of the radioimmunoconjugate, increasing the therapeutic index from 7.3 to 11.8. This overall tumor response was similar to mice pretreated with GEM prior to injection with [212]Pb-trastuzumab.[4] GEM increases the survival of mice receiving either [212]Pb-labeled cetuximab or trastuzumab by 1.6-fold. Treatment of tumor-bearing mice with carboplatin appears to inhibit or suppress the therapeutic efficacy of [212]Pb-cetuximab. This result is contrary to what was observed when tumor-bearing mice were treated with carboplatin in combination with [212]Pb-trastuzumab.[3] An evaluation of paclitaxel in combination with [212]Pb-cetuximab has yet to be performed.

The heterogeneous nature of tumors presents an obstacle to delivering a therapeutic radiation dose throughout a tumor mass.[41] Fortunately, an advantage of RIT is that not all cells in a tumor need express the target molecule nor does that molecule need to be expressed in high numbers. Neighboring cells may receive cytotoxic doses, courtesy of the omnidirectional decay of radioactivity. α-Particle radiation provides an additional benefit. Estimates are that only 3 to 6 traversals of a cell nucleus by an α-particle brings about cell death; the dose rate is estimated to be as low as 1 centigray per hour.[42-45] Targeting of multiple antigens in tumors is another strategy for overcoming heterogeneity and thus improving the therapeutic efficacy of RIT.[27-31] A report from this laboratory demonstrated that this approach is feasible for α-particle-targeted radiation therapy.[30] The concurrent administration of [213]Bi-labeled trastuzumab and the [213]Bi-labeled humanized ΔCH2 variant of CC49 resulted in an enhanced, additive, therapeutic benefit. Co-injection of these 2 [213]Bi-labeled antibodies extended the MS of mice bearing i.p. tumors by almost 5-fold compared to mice treated with either antibody alone.[30] Although the approach of combining antibodies to target multiple antigens was not without precedence, the studies had been conducted with β[−]-emitting radionuclides. Prior to the present study, and the earlier report from this laboratory, the therapeutic efficacy of α-radiation using [213]Bi-labeled antibodies, has been evaluated in vitro with prostate cancer cells, grown in monolayer or as spheroids.[46-48] In the present study, the extension of the MS of mice treated with the combination of [212]Pb-labeled cetuximab and trastuzumab added an additional 37 and 72 d, respectively. This improved therapy was clearly specific because mice treated with a combination of [212]Pb-labeled cetuximab and HuIgG or trastuzumab and HuIgG experienced only modest improvements in the MS. To better understand the therapeutic effect of dual targeting with cetuximab and trastuzumab, studies are currently underway investigating the expression and distribution of both HER2 and HER1 in the LS-174T i.p. tumor xenografts.

As these studies with [212]Pb-cetuximab may be translated to a clinical trial, as was [212]Pb-trastuzumab, the evaluation of this radioimmunoconjugate will move forward. Future studies will include those required for the filing of an investigational new drug application, e.g., evaluation of the stability of both cetuximab-TCMC and [212]Pb-cetuximab. Studies are also proposed to elucidate mechanisms associated with [212]Pb-cetuximab therapy, as well as the dual targeting [212]Pb RIT and the combination therapy with chemotherapeutics.

In summary, as a vehicle for the targeting of α-particle radiation, cetuximab was effective in extending the median survival of mice bearing i.p. tumor xenografts. This therapeutic efficacy was enhanced by chemotherapeutics, as well as by the targeting of 2 antigens expressed by the i.p. LS-174T tumor xenografts. The studies demonstrate that, with careful consideration of cancer cell targets and targeting vehicles along with methodical evaluation, [212]Pb-RIT has enormous potential to provide effective therapies

for cancer. It remains clear that despite the exquisite therapeutic impact delivered by a single dose of a singularly-targeted α-therapeutic agent, that integration of this modality with both chemotherapeutics as well as delivery to multiple molecular targets, e.g., HER2, HER1, should prove most efficacious for treating cancer. The studies described herein represent another step toward providing choices of treatment for cancer patients.

Materials and Methods

Ethics statements
All animal protocols were approved by the National Cancer Institute Animal Care and Use Committee.

Cell lines
Media and supplements were purchased from Lonza unless otherwise indicated. Therapy studies were conducted using the LS-174T, a human colon carcinoma cell line, grown in Dulbecco's minimum essential medium (12–614Q). The medium was supplemented with 1 mM glutamine 17–605E), 10% FetalPlex (Gemini Bioproducts, Inc.; 100–602) and 1 mM non-essential amino acids 13–114E) as previously described.[49,50]

Chelate synthesis and mAb conjugation
Cetuximab (Erbitux®; Amgen, Inc.), was purchased through the National Institute of Health (NIH), Division of Veterinary Resources Pharmacy. Conjugation of cetuximab with the bifunctional ligands, TCMC and CHX-A"-DTPA, was performed according to established methods that have been previously described in detail.[51,52] The final concentration of cetuximab was determined by the Lowry method using a BSA standard.[53] The number of CHX-A"-DTPA or TCMC molecules linked to cetuximab was quantitated using spectrophotometric assays based on the titration of either yttrium- or lead-Arsenazo(III) complex, respectively.[54,55] Polyclonal HuIgG (MP Biochemicals; 64145), chosen to serve as a negative control in these studies, was similarly conjugated with CHX-A"-DTPA or TCMC in parallel and evaluated as described above. The HuIgG is purified from human serum, and to date no known antigen has been described with which it reacts. Trastuzumab, conjugated with TCMC, was utilized in one study to allow a direct comparison of the therapeutic efficacy of cetuximab to that of trastuzumab when radiolabeled with ^{212}Pb.

Radiolabeling
Radiolabeling of CHX-A"-cetuximab (50 μg in 100 μL of 0.15 M NH$_4$OAc buffer, pH 7.0) with ^{111}In (PerkinElmer) has been detailed elsewhere.[23] For these studies, ^{212}Pb was obtained from a ^{224}Ra/^{212}Pb generator (AlphaMed, Inc..). Elution of the ^{212}Pb and radiolabeling of cetuximab-, trastuzumab- and HuIgG-TCMC" was performed as previously described.[2,7]

Radioimmunoassays
The immunoreactivity of the cetuximab-TCMC conjugate was evaluated in a competition radioimmunoassay as outlined in an earlier publication using purified human epidermal growth factor receptor (EGFR; Sigma-Aldrich, E3641–500UN).[56] Briefly, EGFR was allowed to adsorb to the wells of a 96-well plate, the EGFR was removed and 1% bovine serum albumin in phosphate buffered saline (BSA/PBS; 100 μL) was added to each well. Following a 0.5–1 h incubation at room temperature, the solution was removed and serial dilutions of the immunoconjugate (500 to 0.01 ng in 25 μL) in BSA/PBS were added to the wells in triplicate. Following the addition of ^{125}I-cetuximab (50,000 cpm/25 μL) to each of the wells, the plates were incubated 4 h at 37°C. The wells were washed, the radioactivity dissociated from the wells with 0.1 M NaOH (100 μL), adsorbed to cotton filters and counted in a γ-scintillation counter. The immunoconjugate was compared to unmodified cetuximab. The percent inhibition was calculated using the buffer control and plotted. HuM195, a mAb that reacts with human CD33, served as a negative control.

The immunoreactivity of the ^{111}In- and ^{212}Pb-cetuximab was assessed in a radioimmunoassay using purified EGFR (100 ng per well). After absorption of EGFR to the wells of a 96-well plate, the EGFR was removed and the wells treated as described above. Serial dilutions of radiolabeled cetuximab (~200,000 cpm to 12,500 cpm in 50 μL of BSA/PBS) were added to the wells and incubated for 4 h incubation at 37°C. The wells were washed, the radioactivity harvested and counted in a γ-scintillation counter again as just described. The percentage binding was calculated for each dilution and averaged. The specificity of the radiolabeled cetuximab was confirmed by incubating one set of wells with radiolabeled cetuximab and 10 μg of unlabeled cetuximab.

In Vivo Studies
All in vivo studies were performed using 5 - 6 week old female athymic (NCr-nu/nu) mice (NCI-Frederick, Cat#01B70).

Tumor targeting
Mice were injected intraperitoneally (i.p.) with 1×10^8 LS-174T cells in 1 mL of medium and utilized in tumor targeting studies 5 d later. Mice (n = 5) were injected i.p. with ^{111}In-CHX-A"-cetuximab (~7.5 μCi on 0.6 μg) and euthanized 24 to 168 h by exsanguination. The blood, tumor and major organs were collected, wet-weighed, and counted in a γ-scintillation counter. The percent injected dose per gram (%ID/g) and standard deviation were calculated.

Therapy
RIT studies detailed below were initiated at 2–3 d following i.p. injection with LS-174T as described above. ^{212}Pb-trastuzumab (10 μCi), was administered i.p. to mice in 0.5 mL PBS. ^{212}Pb-HuIgG served as a non-specific control in these studies. The mice were monitored daily and body weight was measured and recorded 1–2 times per week for 4–6 weeks as a measure of toxicity due to therapy. Progression of disease was observed either as an extension of the abdomen, development of ascites or noticeable, palpable, nodules in the abdomen or, conversely, as weight loss. Mice were euthanized if found to be in distress, moribund,

or cachectic. Euthanasia was also performed when a 10–20% weight loss occurred, or when disease progression was evident as cited above.

Study 1 was conducted to establish the effective working dose of [212]Pb-cetuximab for the therapy of HER1-positive i.p. tumor xenografts. Tumor-bearing mice (n = 10) were given increasing doses of [212]Pb-cetuximab (10, 20, 30 and 40 μCi) by i.p. injection, [212]Pb-HuIgG (20 and 40 μCi) or no RIT.

A subsequent experiment (Study 2) was conducted to confirm the effective working dose of 10 uCi. This study was also performed to directly compare the therapeutic efficacy of targeting HER1 with [212]Pb-cetuximab to that of [212]Pb-trastuzumab targeting of HER2. Mice (n = 10) bearing i.p. LS-174T xenografts were injected (i.p.) with 10 μCi of [212]Pb-labeled cetuximab, trastuzumab or HuIgG. An additional set of mice were injected with 2 mg of unlabeled cetuximab to assess the potential contribution that the mAb as a stand-alone therapeutic would have toward therapy of the LS-174T tumor xenografts.

The studies with [212]Pb-cetuximab were then extended to investigate potential enhancement of therapeutic efficacy by the inclusion of chemotherapeutics in the treatment regimen. Studies were conducted with gemcitabine (GEMZAR; Eli Lilly and Company) and carboplatin (Hospira, Inc.). Both chemotherapeutics were purchased through the NIH, Division of Veterinary Resources Pharmacy. In Study 3, mice (n = 10) bearing i.p. LS-174T tumors were injected i.p. with 1 mg of gemcitabine (GEM) or 1.25 mg of carboplatin, 2 d post tumor cell implantation, followed 24 h later with [212]Pb-cetuximab (10 μCi). The decision to administer the carboplatin 24 h before [212]Pb-cetuximab was based on data obtained with [212]Pb-trastuzumab.[3] These treatment groups were compared to mice pre-treated with GEM or carboplatin followed by [212]Pb-HuIgG. Control groups included mice receiving no treatment, [212]Pb-cetuximab, [212]Pb-HuIgG, carboplatin or GEM only.

Lastly, a pilot study (Study 4) was conducted to determine whether or not the concurrent targeting of HER2 and HER1 expressed on a tumor would provide greater therapeutic benefit. Tumor-bearing mice were given a single i.p. administration of a solution containing 5 μCi of each antibody (10 μCi total) [212]Pb-cetuximab / [212]Pb-trastuzumab, [212]Pb-cetuximab / [212]Pb-HuIgG, or [212]Pb-HuIgG / [212]Pb-trastuzumab. Other treatment groups included each of the [212]Pb-labled antibodies at 10 μCi and one group of mice that were not treated.

Statistical analyses

Kaplan-Meier survival (time to sacrifice or natural death) analysis was conducted using SigmaPlot 12.5; groups were compared using a log-rank test. A pairwise comparison was performed to test for differences between treatment groups (Holm-Sidak method). All reported p-values correspond to 2-sided tests.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Supplemental Material

Supplemental data for this article can be accessed on the publisher's website.

References

1. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004; 10:7834-41; PMID:15585615; http://dx.doi.org/10.1158/1078-0432.CCR-04-1226

2. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005; 20:557-68; PMID:16248771; http://dx.doi.org/10.1089/cbr.2005.20.557

3. Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW. Evaluation of platinum chemotherapy in combination with HER2-targeted alpha-particle radiation. Cancer Biother Radiopharm 2013; 28:441-9; PMID:23758610; http://dx.doi.org/10.1089/cbr.2012.1423

4. Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, Brechbiel MW. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 2007; 13:1926-35; PMID:17363549; http://dx.doi.org/10.1158/1078-0432.CCR-06-2300

5. Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ, Flynn J, Brechbiel MW. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 2008; 14:5108-15; PMID:18698028; http://dx.doi.org/10.1158/1078-0432.CCR-08-0256

6. Howell RW, Azure MT, Narra VR, Rao DV. Relative biological effectiveness of alpha-particle emitters in vivo at low doses. Radiat Res 1994; 137:352-60; PMID:8146279; http://dx.doi.org/10.2307/3578710

7. Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol 2013; 40:592-9; PMID:23602604; http://dx.doi.org/10.1016/j.nucmedbio.2013.01.010

8. Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, Carlise R, Bunch P, Yoder D, Alvarez R. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm 2014; 29:12-7; PMID:24229395; http://dx.doi.org/10.1089/cbr.2013.1531

9. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 2012; 11:639-48; PMID:22238365; http://dx.doi.org/10.1158/1535-7163.MCT-11-0671

10. Yong KJ, Milenic DE, Baidoo KE, Kim YS, Brechbiel MW. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model. Cancer Med 2013; 2:646-53; PMID:24403230

11. Agus DB, Bunn PA, Jr., Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27:53-63; discussion 92-100.

12. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45:457-61; PMID:1968437; http://dx.doi.org/10.1002/ijc.2910450314

13. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19:554-68; PMID:11458821; http://dx.doi.org/10.1081/CNV-100103852

14. Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ, Jr. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 2012; 7:e49829; PMID:23189165

15. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11:689-708; PMID:15613446; http://dx.doi.org/10.1677/erc.1.00600

16. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94:1593-611; PMID:11920518; http://dx.doi.org/10.1002/cncr.10372

17. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001; 13:506-13; PMID:11673692; http://dx.doi.org/10.1097/00001622-200111000-00014

18. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025

19. Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor

receptor-expressing tumours. Expert Opin Pharmacother 2004; 5:1621-33; PMID:15212612; http://dx.doi.org/10.1517/14656566.5.7.1621

20. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8; PMID:18003960; http://dx.doi.org/10.1056/NEJMoa071834

21. Guo Y, Parry JJ, Laforest R, Rogers BE, Anderson CJ. The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer. J Nucl Med 2013; 54:1621-9; PMID:23873478; http://dx.doi.org/10.2967/jnumed.112.118539

22. Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F. Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model. Mol Pharm 2014; 11: 800-807; http://dx.doi.org/10.1021/mp4005047

23. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008; 23:619-31; PMID:18999934; http://dx.doi.org/10.1089/cbr.2008.0493

24. Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS One 2011; 6: e18198; PMID:21464917; http://dx.doi.org/10.1371/journal.pone.0018198

25. Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 2010; 37:1368-76; PMID:20155263; http://dx.doi.org/10.1007/s00259-009-1370-z

26. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46:1898-906; PMID:16269605

27. Gaffar SA, Pant KD, Shochat D, Bennett SJ, Goldenberg DM. Experimental studies of tumor radioimmunodetection using antibody mixtures against carcinoembryonic antigen (CEA) and colon-specific antigen-p (CSAp). Int J Cancer 1981; 27:101-5; PMID:7251228; http://dx.doi.org/10.1002/ijc.2910270116

28. Hillairet de Boisferon M, Raguin O, Dussaillant M, Rostene W, Barbet J, Gruaz-Guyon A. Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens. Bioconjug Chem 2000; 11:452-60; PMID:10898565; http://dx.doi.org/10.1021/bc9901090

29. Hillairet De Boisferon M, Raguin O, Thiercelin C, Dussaillant M, Rostene W, Barbet J, Pelegrin A, Gruaz-Guyon A. Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model. Bioconjug Chem 2002; 13:654-62; PMID:12009958; http://dx.doi.org/10.1021/bc015585g

30. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 2010; 116:1059-66; PMID:20127951; http://dx.doi.org/10.1002/cncr.24793

31. Munz DL, Alavi A, Koprowski H, Herlyn D. Improved radioimmunoimaging of human tumor xenografts by a mixture of monoclonal antibody F(ab')2 fragments. J Nucl Med 1986; 27:1739-45; PMID:3772507

32. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78; PMID:16467544; http://dx.doi.org/10.1056/NEJMoa053422

33. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-8; PMID:19897418; http://dx.doi.org/10.1016/S1470-2045(09)70311-0

34. Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008; 72:534-42; PMID:18793955; http://dx.doi.org/10.1016/j.ijrobp.2008.06.1490

35. Koi L, Bergmann R, Bruchner K, Pietzsch J, Pietzsch HJ, Krause M, Steinbach J, Zips D, Baumann M. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. Radiother Oncol 2014; 110:362-9; PMID:24440046; http://dx.doi.org/10.1016/j.radonc.2013.12.001

36. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med 2010; 51:942-50; PMID:20484421; http://dx.doi.org/10.2967/jnumed.109.071290

37. Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010; 16:2095-105; PMID:20215534; http://dx.doi.org/10.1158/1078-0432.CCR-09-2495

38. Song H, Hedayati M, Hobbs RF, Shao C, Bruchertseifer F, Morgenstern A, Deweese TL, Sgouros G. Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther 2013; 12:2043-54; PMID:23873849; http://dx.doi.org/10.1158/1535-7163.MCT-13-0108

39. Guerard F, Lee YS, Brechbiel MW. Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV). Chemistry 2014; 20:5584-91; PMID:24740517; http://dx.doi.org/10.1002/chem.201304115

40. Guerard F, Lee YS, Tripier R, Szajek LP, Deschamps JR, Brechbiel MW. Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem Commun (Camb) 2013; 49:1002-4; PMID:23250287; http://dx.doi.org/10.1039/c2cc37549d

41. Hand PH, Nuti M, Colcher D, Schlom J. Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens. Cancer Res 1983; 43:728-35; PMID:6848188

42. Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted alpha-particle radiation therapy. Clin Cancer Res 2013; 19:530-7; PMID:23230321; http://dx.doi.org/10.1158/1078-0432.CCR-12-0298

43. Hei TK, Wu LJ, Liu SX, Vannais D, Waldren CA, Randers-Pehrson G. Mutagenic effects of a single and an exact number of alpha particles in mammalian cells. Proc Natl Acad Sci U S A 1997; 94:3765-70; PMID:9108052; http://dx.doi.org/10.1073/pnas.94.8.3765

44. Pugliese M, Durante M, Grossi GF, Monforti F, Orlando D, Ottolenghi A, Scampoli P, Gialanella G. Inactivation of individual mammalian cells by single alpha-particles. Int J Radiat Biol 1997; 72:397-407; PMID:9343105; http://dx.doi.org/10.1080/095530097143176

45. Soyland C, Hassfjell SP. Survival of human lung epithelial cells following in vitro alpha-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells. Int J Radiat Biol 2000; 76:1315-22; PMID:11057739; http://dx.doi.org/10.1080/09553000050151583

46. Li Y, Abbas Rizvi SM, Blair nee Brown JM, Cozzi PJ, Qu CF, Ow KT, Tam PN, Perkins AC, Russell PJ, Allen BJ. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. Int J Radiat Oncol Biol Phys 2004; 60:896-908; PMID:15465208; http://dx.doi.org/10.1016/j.ijrobp.2004.04.035

47. Li Y, Cozzi PJ, Qu CF, Zhang DY, Abbas Rizvi SM, Raja C, Allen BJ. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate. Cancer Lett 2004; 205:161-71; PMID:15036648; http://dx.doi.org/10.1016/j.canlet.2003.10.035

48. Wang J, Abbas Rizvi SM, Madigan MC, Cozzi PJ, Power CA, Qu CF, Morgenstern A, Apostolidis C, Russell PJ, Allen BJ, et al. Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Prostate 2006; 66:1753-67; PMID:16955401; http://dx.doi.org/10.1002/pros.20502

49. Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, Brechbiel MW. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010; 2:550-64; PMID:20716957; http://dx.doi.org/10.4161/mabs.2.5.13054

50. Tom BH, Rutzky LP, Jakstys MM, Oyasu R, Kaye CI, Kahan BD. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976; 12:180-91; PMID:1262041; http://dx.doi.org/10.1007/BF02796440

51. Garmestani K, Yao Z, Zhang M, Wong K, Park CW, Pastan I, Carrasquillo JA, Brechbiel MW. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl Med Biol 2001; 28:409-18; PMID:11395314; http://dx.doi.org/10.1016/S0969-8051(00)00203-1

52. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, Carrasquillo JA, Pastan I, Brechbiel MW. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem 1997; 5:1925-34; PMID:9370037; http://dx.doi.org/10.1016/S0968-0896(97)00130-2

53. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-75; PMID:14907713

54. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999; 26:977-82; PMID:10708314; http://dx.doi.org/10.1016/S0969-8051(99)00054-2

55. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 1992; 3:342-5; PMID:1390990; http://dx.doi.org/10.1021/bc00016a014

56. Ray GL, Baidoo KE, Wong KJ, Williams M, Garmestani K, Brechbiel MW, Milenic DE. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol 2009; 157:1541-8; PMID:19681874; http://dx.doi.org/10.1111/j.1476-5381.2009.00327.x